StreetInsider.com News Articles

Form 8-K Jasper Therapeutics, For: Jul 16

Fri, 17 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260717/26781510.html

Form 8-K Jasper Therapeutics, For: Jul 16

Fri, 17 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260717/26781510.html

Jasper Therapeutics completes Kira acquisition, raises $132M

Thu, 16 Jul 2026 17:16:29 -0400

Jasper Therapeutics (Nasdaq: JSPR) has completed its acquisition of Kira Pharmaceuticals in an all-stock transaction, according to a press release. Concurrent with the deal, Jasper raised approximately $132 million through a private placement of non-voting convertible preferred stock.

The private placement was co-led by Affinity Asset Advisors and Ikarian Capital, with participation from Columbia Threadneedle Investments, Balyasny Asset Management, Mirador Therapeutics, and other investors. The offering is expected to close July 20, 2026.

As part of the transaction, Kira out-licensed two assets — KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist — to Mirador Therapeutics for

Jasper Therapeutics completes Kira acquisition, raises $132M

Thu, 16 Jul 2026 17:16:29 -0400

As part of the transaction, Kira out-licensed two assets — KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist — to Mirador Therapeutics for

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Thu, 16 Jul 2026 17:15:00 -0400

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders

Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics

Kira out-licenses KP-301, a long-acting anti-C5a monoclonal antibody, and KP-402, a small molecule C5a receptor antagonist, to Mirador Therapeutics, for $12 million upon signing and potential development and sales milestone payments

Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones

REDWOOD CITY, Calif. and CAMBRIDGE,

Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Thu, 16 Jul 2026 17:15:00 -0400

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders

Concurrent $132 million private investment with participation from leading life sciences investors and Mirador Therapeutics

Combined financing and transactions expected to fund combined company operations through the second half of 2028, including multiple clinical milestones

REDWOOD CITY, Calif. and CAMBRIDGE,

Form 8-K Jasper Therapeutics, For: Jul 16

Thu, 16 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260716/26780578.html

Form 8-K Jasper Therapeutics, For: Jul 16

Thu, 16 Jul 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260716/26780578.html

Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Fri, 10 Jul 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260710/26758202.html

Form SCHEDULE 13G/A Jasper Therapeutics, Filed by: INTEGRATED CORE STRATEGIES (US) LLC

Fri, 10 Jul 2026 18:20:00 -0400

si-local-file:///var/storage/secattach/20260710/26758202.html

Form ARS Jasper Therapeutics, For: Dec 31

Mon, 15 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260615/26647284.html

Form ARS Jasper Therapeutics, For: Dec 31

Mon, 15 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260615/26647284.html

Form DEFA14A Jasper Therapeutics,

Mon, 15 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260615/26647224.html

Form DEFA14A Jasper Therapeutics,

Mon, 15 Jun 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260615/26647224.html

Form DEF 14A Jasper Therapeutics, For: Jul 31

Mon, 15 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26647213.html

Form DEF 14A Jasper Therapeutics, For: Jul 31

Mon, 15 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260615/26647213.html

Form 8-K Jasper Therapeutics, For: Jun 03

Tue, 09 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26623638.html

Form 8-K Jasper Therapeutics, For: Jun 03

Tue, 09 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260609/26623638.html

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

Jasper Therapeutics Inc. (NASDAQ: JSPR) announced that its board of directors has initiated a review of strategic alternatives aimed at maximizing shareholder value. The clinical-stage biotechnology company said it is evaluating options including asset sales, licensing agreements, collaborations, a company sale, business combination, merger or an orderly wind-down of operations.

The Redwood City, California-based company develops briquilimab, an antibody therapy targeting c-Kit to address mast cell driven diseases such as chronic spontaneous urticaria, chronic inducible urticaria and asthma. Jasper said it will continue evaluating cost-saving measures to preserve cash while maintaining regulatory and financial reporting compliance during the strategic review.

The company

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

The company

Jasper Therapeutics explores strategic alternatives including potential sale

Mon, 01 Jun 2026 08:01:52 -0400

The company

Form 8-K Jasper Therapeutics, For: Jun 01

Mon, 01 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26579593.html

Form 8-K Jasper Therapeutics, For: Jun 01

Mon, 01 Jun 2026 08:01:00 -0400

si-local-file:///var/storage/secattach/20260601/26579593.html

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that, following an evaluation of current market conditions, its Board of Directors has decided to initiate a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale

Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Mon, 01 Jun 2026 08:00:00 -0400